Compass gets a White House tailwind

The government just hit the gas

Compass Pathways was already trying to convince Wall Street that psilocybin isn’t just Silicon Valley wellness cosplay. Now the White House is basically saying: let’s stop dragging our feet on psychedelic treatments and see what the science can do.

Why Compass is suddenly in the spotlight

The company says its synthetic psilocybin therapy, COMP360, posted strong late-stage data in treatment-resistant depression, with symptom improvement in as little as one day for some patients and benefits lasting months in responders. That’s the kind of result that makes investors sit up a little straighter.

The real kicker: faster reviews

Trump’s executive order directs the FDA to fast-track psychedelic-based therapies, including ibogaine, and even set aside $50 million for research. For Compass, that matters because it could shave time off the long, annoying trek from “interesting data” to “please approve this already.” The company is also working with the FDA on a rolling submission for potential approval and keeping PTSD trials moving.

Big picture

This doesn’t magically approve COMP360, but it does change the vibe around the category. When regulators start talking urgency instead of caution, biotech investors usually hear one thing: the runway just got a lot less foggy.